Coherus BioSciences Enters New Cancer Treatment Collaboration, Projects Significant Revenue Growth

Coherus BioSciences (CHRS) has partnered with STORM Therapeutics to explore the effects of combining METTL3 inhibitor STC-15 with PD-1 inhibitor LOQTORZI in a Phase 1b/2 clinical trial for various cancers, including NSCLC, HNSCC, melanoma, and endometrial cancer. The collaboration aligns with Coherus' strategy to broaden LOQTORZI's use beyond its current indications. Wall Street analysts forecast an average target price of $4.68, indicating a 519.41% upside from the current price of $0.76.